Drug intelligence / Profile preview

methylene blue + technetium-99m sulfur colloid

Development stage: Unknown
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intradermal, Subcutaneous, Peritumoral, Subareolar, Intraparenchymal

Overview

A combination of methylene blue dye and technetium-99m sulfur colloid used primarily for sentinel lymph node biopsy (SLNB) in breast cancer and melanoma patients. The combination provides both visual identification through blue staining (methylene blue) and radioactive detection capabilities (technetium-99m), resulting in higher detection rates and lower false-negative rates compared to using either agent alone.

Beyond the preview

Go deeper on methylene blue + technetium-99m sulfur colloid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylene blue + technetium-99m sulfur colloid.

Explore the full profile